iCardiac acquires nSpire Health’s clinical trials division
iCardiac Technologies, a Rochester, N.Y.-based global provider of cardiac safety assessment services to the pharmaceutical industry, has added respiratory and ePRO services to its suite of offerings through the acquisition of the clinical trials division of nSpire Health. iCardiac also has opened a new office in Longmont, Colo., to accommodate the project management, data management, customer support, IT, technology development and business development teams joining iCardiac from nSpire Health.
nSpire Health has conducted more than 225 clinical trials during the past decade, providing centralized spirometry, pulmonary diagnostics, challenge testing, eDiary and data management services for phase I-IV studies. It has worked with more than 5,400 investigative sites in 55 countries.
“iCardiac and nSpire have worked side by side as closely integrated partners for over five years and on over 20 clinical trials,” said Alex Zapesochny, president and chief operating officer of iCardiac.
With the sale of its clinical trials division, nSpire Health will focus on developing and expanding its commercial healthcare business and also will serve as an equipment supplier to iCardiac for clinical trials applications.
No financial terms of the deal were disclosed. The transaction is effective immediately.